GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harvard Apparatus Regenerative Technology Inc (OTCPK:HRGN) » Definitions » Financial Strength

Harvard Apparatus Regenerative Technology (Harvard Apparatus Regenerative Technology) Financial Strength : 5 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Harvard Apparatus Regenerative Technology Financial Strength?

Harvard Apparatus Regenerative Technology has the Financial Strength Rank of 5.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Harvard Apparatus Regenerative Technology has no long-term debt (1). Harvard Apparatus Regenerative Technology's debt to revenue ratio for the quarter that ended in Dec. 2023 was 0.19. As of today, Harvard Apparatus Regenerative Technology's Altman Z-Score is -40.62.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.


Competitive Comparison of Harvard Apparatus Regenerative Technology's Financial Strength

For the Biotechnology subindustry, Harvard Apparatus Regenerative Technology's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harvard Apparatus Regenerative Technology's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harvard Apparatus Regenerative Technology's Financial Strength distribution charts can be found below:

* The bar in red indicates where Harvard Apparatus Regenerative Technology's Financial Strength falls into.



Harvard Apparatus Regenerative Technology Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Harvard Apparatus Regenerative Technology's Interest Expense for the months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the months ended in Dec. 2023 was $-1.82 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.

Harvard Apparatus Regenerative Technology's Interest Coverage for the quarter that ended in Dec. 2023 is

Harvard Apparatus Regenerative Technology had no long-term debt (1).

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Harvard Apparatus Regenerative Technology Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Harvard Apparatus Regenerative Technology's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.048 + 0) / 0.252
=0.19

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Harvard Apparatus Regenerative Technology has a Z-score of -40.62, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -40.62 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harvard Apparatus Regenerative Technology  (OTCPK:HRGN) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Harvard Apparatus Regenerative Technology has the Financial Strength Rank of 5.


Harvard Apparatus Regenerative Technology Financial Strength Related Terms

Thank you for viewing the detailed overview of Harvard Apparatus Regenerative Technology's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Harvard Apparatus Regenerative Technology (Harvard Apparatus Regenerative Technology) Business Description

Traded in Other Exchanges
N/A
Address
84 October Hill Road, Suite 11, Holliston, MA, USA, 01746
Harvard Apparatus Regenerative Technology Inc is a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastrointestinal system and the airway resulting from cancer, trauma, or birth defects. The company's technology is based on its proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs.
Executives
Junli He director C/O NO.1, COUNTRY GARDEN ROAD, BEIJIAO TOWN, SHUNDE DISTRICT, FOSHAN F4 528300
James E. Shmerling director 975 JOHNSON FERRY ROAD, SUITE 450, ATLANTA GA 30342
Dst Capital Llc 10 percent owner C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Ronald J Packard director 2300 CORPORATE PARK DRIVE, HERNDON VA 20171
Jing Chen director C/O BIOSTAGE,INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 02110
Hong Yu officer: President C/O BIOSTAGE, INC. 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Damasio Joseph Luis Jr officer: Chief Financial Officer 14 NORFOLK AVENUE, SOUTH EASTON MA 02375
David Green director, officer: See Remarks C/O HARVARD BIOSCIENCE INC, 84 OCTOBER HILL ROAD, HOLLISTON MA 01746-1371
William Fodor officer: Chief Scientific Officer C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Peter A. Pellegrino officer: Interim VP of Finance C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Herman Sanchez director 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON MA 01746
James Mastridge officer: See Remarks C/O BIOSTAGE, INC., 84 OCTOBER HILL RD., HOLLISTON MA 01746
Jeffrey E Young director 60 WESTVIEW STREET, LEXINGTON MA 02421
Wei Zhang director C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Ting Li director C/O BIOSTAGE, INC., 84 OCTOBER HILL RD., HOLLISTON MA 01746